Alkermes (NASDAQ:ALKS) had its price target raised by analysts at Bank of America Corporation from $33.00 to $34.00. They now have a "neutral" rating on the stock.
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]
Alkermes (NASDAQ:ALKS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.